Skip to main content

Table 2 Epidemiologic parameters at the time of consultation

From: Interdisciplinary decision making in prostate cancer therapy – 5-years’ time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin

  Cohort I Cohort II p-value*
(SD and/or range) (SD and/or range)
Age (mean) 66.44 69.31 .001
Life expectancy (mean) 17.22 14.75 .001
  >15 y (%) 70.9 40.8
Clinical stage (%)    
  T1a-c 66.1 74.4 .602
  T2a-c 28.8 22.3
  T3 1.1 0.5
  T4 0.7 0.5
PSA value( μg/l) 7.98 ± 22.59 (0.4-311) 7.6 ± 15.66 (0.88-120) .392
Organ confined (Partin; mean; %) 61.1 58.9 .324
Risk groups (D´Amico; %)    
  low-risk 50.9 37.2 .066
  intermediate risk 28.2 39.6
  high risk 20.9 23.2
Charlson comorbidity score 0.41 (0–6) 0.39 (0–6) .787
Biochemical failure free survival (Kattan; %)    
  RP 79.8 79.2 .735
  EBRT 79.3 79.8 .657
Gleason score of biopsy (median) 6 ± 1.43 6.59 ± 0.99 <.001
Number of biopsy cores 8.43 ± 2.29 (2–14) 9.95 ± 2.38 (2–20) <.001
Prostate volume (ml) 40.16 ± 15.64 41.75 ml ± 19.56 .689
  1. *Student´s T-test and Chi-Square-test as appropriate; Epidemiologic parameters at the time of consultation; mean age in years; mean life expectancy and percentage of patients with life expectancy >15 years; clinical stage (in %; missing clinical stage: 3.3% in Cohort I and 2.3% in Cohort II); PSA value in μg/l; percentage of organ confined disease according to Partin 2007; risk group stratification according to D´Amico (in %); Charlson comorbidity score; 5-years biochemical failure free survival according to Kattan nomogram (in %); median Gleason score of biopsy; number of biopsy cores; prostate volume in ml.